BOSTON--(BUSINESS WIRE)--ZappRx announced today that it has entered into an agreement with Genentech. The agreement will start by seeking to improve patient access to specialty drugs in IPF, with an option to continue in allergic asthma, and chronic idiopathic urticaria.
ZappRx’s goal is to develop an industry-first digital platform for specialty drugs, using a data-driven approach to solving the challenges with today’s paper-based, manual, and time-consuming processes currently associated with ordering specialty drugs. ZappRx’s specialty ordering and fulfillment platform allows for the digitization of existing paper-based and manual workflows and for the analysis of real-time, pre-fulfillment data to enable value-based health care.
Clinicians using the ZappRx technology can now select the treatment of their choice from the specialty drugs indicated in a therapeutic area using a standardized workflow on one platform. This platform is capable of connecting to relevant stakeholders and can help enable patients to get access to the prescribed treatment as soon as possible.
Zoë Barry, ZappRx Founder and CEO, said, “We are thrilled to enter into an agreement with Genentech, a company who is on the leading edge of helping patients with innovative solutions. Like Genentech, ZappRx is committed to pursuing solutions intended to improve the lives of patients. I’m personally excited to see that others share my dream of making access to specialty drugs better, faster, and more transparent for patients.”
About ZappRx
ZappRx streamlines the complex process required to
order specialty medications, increasing efficiencies when collecting and
maintaining the myriad requisite information for ordering specialty
drugs — including pharmacy information, payer/prior authorization
requirements, and relevant clinical history. ZappRx then enables
providers, pharmacists, and payers to digitally interact with one
another to fill a prescription, reducing the need for faxes and phone
calls. The platform currently is live in Pulmonary (including Cystic
Fibrosis (CF), Pulmonary Arterial Hypertension (PAH), and Idiopathic
Pulmonary Fibrosis (IPF)), Cardiology (including Hyperlipidemia and
Congestive Heart Failure), and Gastroenterology (including Crohn’s
Disease and Ulcerative Colitis). As the company grows, ZappRx plans to
expand into other areas, including Rheumatology, Neurology, and Oncology.
Connect with ZappRx on Twitter (@ZappRx) and LinkedIn (https://www.linkedin.com/company/zapprx/)
